株式会社バイオロジカ

株式会社バイオロジカ 研究用試薬機器の輸入販売とDNA型親子鑑定サービスの提供 DNAや合成ペプチド・抗体などの受託合成をはじめ、研究試薬を販売しております。また、質量分析やHPLC関連の機器も取り扱っております。一般の方向けにはDNA型親子鑑定サービスを提供しております。

04/09/2026

Norovirus remains an important cause of acute gastroenteritis worldwide, making the development of effective vaccines an important area of infectious disease research.

Current vaccine strategies include virus-like particle (VLP)-based candidates and oral vaccine approaches designed to stimulate protective immune responses. However, the broad genetic and antigenic diversity of noroviruses continues to present significant challenges for developing vaccines with broad and durable protection.

• Explore the norovirus genome and life cycle
• Learn about current vaccine development strategies
• Understand key challenges in vaccine research
• Discover antibody pairs and neutralizing antibodies supporting norovirus studies

Learn more from Creative Diagnostics:
https://www.creative-diagnostics.com/development-of-norovirus-vaccines.htm

03/09/2026

Plasmid DNA in Biopharma: Key Challenges & Quality Control

Plasmid DNA is an essential component in DNA and mRNA vaccines, gene and cell therapies, recombinant proteins, and synthetic biology. As programs move toward clinical and commercial development, plasmid quality becomes increasingly important.

Yaohai Bio-Pharma provides integrated plasmid DNA CDMO capabilities from process development and scale-up to GMP manufacturing and quality control.

Contact us: [email protected]
















02/09/2026

Untargeted lipidomics finds the candidates. Targeted lipidomics proves them.

It's a familiar story in lipid research: your untargeted screen flags dozens of interesting species, but turning those hits into publishable, absolute quantities across a full cohort is another challenge entirely.

That's where a targeted approach makes the difference. Our targeted lipidomics service covers:

✔ 8 lipid categories and 50+ subclasses — over 2,400 lipid molecular species
✔ LC-MS/MS in MRM mode plus GC-MS platforms
✔ Absolute quantification with stable isotope-labeled internal standards
✔ Detection limits down to the low-picomole range, CV

01/09/2026

Tuberculosis (TB) remains a major global health challenge, and developing more effective vaccines against Mycobacterium tuberculosis (M. tuberculosis) is an ongoing research priority.

The BCG vaccine provides important protection against severe forms of TB in children, but its protection against adult pulmonary TB is variable.

Our latest technical overview explores key approaches to TB vaccine development:

• Whole-cell-derived vaccines
• Adjuvanted protein subunit vaccines
• Recombinant viral-vectored vaccines
• DNA vaccine approaches
• Strategies to enhance cellular and humoral immunity
• Heterologous prime-boost vaccination strategies

Understanding how M. tuberculosis interacts with alveolar macrophages, induces granuloma formation, and modulates host immunity is essential for designing next-generation vaccines.

The emergence of drug-resistant M. tuberculosis further highlights the need for improved preventive strategies.

Explore the full technical overview:

https://www.creative-diagnostics.com/development-of-m-tuberculosis-vaccines.htm

27/08/2026

Epstein–Barr virus (EBV), also known as human herpesvirus 4 (HHV-4), is the first identified human oncogenic virus and can establish lifelong persistence in the host.

Its association with infectious mononucleosis, multiple cancers, and autoimmune diseases makes EBV vaccine development an important area of research.

Our latest overview explores key approaches to EBV vaccine development:

• Neutralizing antibody targets including gp350, gH/gL, gB, and gp42
• T-cell targets such as EBNA1 and EBNA2
• Recombinant EBV envelope protein vaccines
• Virus-like particle (VLP) vaccines
• mRNA vaccine approaches
• Viral-vector vaccines for therapeutic applications

A major challenge is developing vaccines that can effectively prevent EBV infection of both B cells and epithelial cells while generating durable humoral and cellular immunity.

Explore the full technical overview:

https://www.creative-diagnostics.com/development-of-epstein-barr-virus-vaccine.htm

26/08/2026

Cytokine storms can cause more tissue damage than the original pathogen. Measuring 21 inflammatory mediators in a single 50-microliter sample — that is what our Human Cytokine Storm 21-Plex Luminex Panel delivers.

Using Luminex xMAP technology, we simultaneously quantify IL-6, IL-1beta, TNF-alpha, IFN-gamma, IL-10, IL-8, IL-12p70, IL-17A, and 13 more analytes from one well. Pg/mL sensitivity. 8-point standard curves. Validated for serum, plasma, CSF, and culture supernatant.

Because cytokine biology is network biology — one mediator in isolation misses the cross-talk and feedback loops that define immune pathology.

Applications: CAR-T cytokine release syndrome, anti-inflammatory drug screening, vaccine immunogenicity, sepsis research.

Full analyte list and sample requirements: https://cytokine.creative-proteomics.com/human-cytokine-storm-panel-service.htm

25/08/2026

Human cytomegalovirus (HCMV), also known as human herpesvirus 5 (HHV-5), is a major research focus in infectious disease and vaccine development.

Congenital HCMV infection can cause serious long-term consequences in newborns, including hearing loss, neurodevelopmental delay, and brain damage. Yet, there is currently no licensed HCMV vaccine.

Our latest overview explores key aspects of HCMV vaccine research:

• HCMV genome and structural organization
• Innate and adaptive immune responses
• Neutralizing antibody targets including gB, gH, and the pentameric complex
• T-cell antigens such as pp65 and IE1
• Live-attenuated and subunit vaccines
• Viral vector, DNA, and RNA vaccine approaches
• Virus-like particles and peptide vaccines
• The emerging role of the pentameric complex in vaccine design

Understanding both antibody-mediated and cellular immunity is essential for advancing next-generation HCMV vaccines.

Explore the full technical overview:

https://www.creative-diagnostics.com/development-of-cytomegalovirus-hhv-5-vaccines.htm

24/08/2026

Adenoviruses are widespread pathogens associated with respiratory disease, pneumonia, conjunctivitis, cystitis, and gastroenteritis.

With more than 100 serologically distinct adenovirus types identified, including 49 human adenovirus types, developing effective vaccines and research tools requires a detailed understanding of adenovirus biology and antigenic diversity.

Our latest overview explores:

• Adenovirus structure and genome organization
• Major capsid proteins, including hexon, penton, and fiber
• Adenovirus DNA replication mechanisms
• The development of Ad4 and Ad7 vaccines
• Live oral adenovirus vaccine strategies
• Advances in adenovirus biology and vaccine research

Creative Diagnostics also provides a broad range of Adenovirus research reagents, including antibodies, native and recombinant antigens, and ELISA kits for different adenovirus types.

Explore the full overview:

https://www.creative-diagnostics.com/adenovirus-vaccines.htm

21/08/2026

Creative Biogene's circRNA research platform integrates high-throughput sequencing (RNA-Seq), high-density microarray analysis, functional validation assays (gain- and loss-of-function), and circRNA–miRNA/RBP interaction studies, providing an end-to-end solution for basic research, translational medicine, drug target discovery, and biomarker identification. https://www.creative-biogene.com/services/circrna-service.html

住所

中区大須4-10/40
Nagoya-shi, Aichi
4600011

営業時間

月曜日 10:00 - 17:00
火曜日 10:00 - 17:00
水曜日 10:00 - 17:00
木曜日 10:00 - 17:00
金曜日 10:00 - 17:00

電話番号

+81522626732

ウェブサイト

アラート

株式会社バイオロジカがニュースとプロモを投稿した時に最初に知って当社にメールを送信する最初の人になりましょう。あなたのメールアドレスはその他の目的には使用されず、いつでもサブスクリプションを解除することができます。

事業に問い合わせをする

株式会社バイオロジカにメッセージを送信:

ショートカット

共有する

カテゴリー